Jan 27 (Reuters) - ‌The ​U.S. ‌Centers for ​Medicare & Medicaid ‍Services on ​Tuesday ​named a ⁠new group of branded drugs ...

By Michael Erman and Deena Beasley Jan 27 (Reuters) - The U.S. government on Tuesday named the 15 new drugs targeted for ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

By Michael Erman SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ...

Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, ...

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named the 15 new drugs targeted for Medicare ...